904 related articles for article (PubMed ID: 28912153)
1. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH
Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153
[TBL] [Abstract][Full Text] [Related]
2. Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors.
Patel RR; Ramkissoon SH; Ross J; Weintraub L
Pediatr Blood Cancer; 2020 Jul; 67(7):e28338. PubMed ID: 32386112
[TBL] [Abstract][Full Text] [Related]
3. Pediatric low-grade gliomas can be molecularly stratified for risk.
Yang RR; Aibaidula A; Wang WW; Chan AK; Shi ZF; Zhang ZY; Chan DTM; Poon WS; Liu XZ; Li WC; Zhang RQ; Li YX; Chung NY; Chen H; Wu J; Zhou L; Li KK; Ng HK
Acta Neuropathol; 2018 Oct; 136(4):641-655. PubMed ID: 29948154
[TBL] [Abstract][Full Text] [Related]
4. Clinical management and genomic profiling of pediatric low-grade gliomas in Saudi Arabia.
Mobark NA; Alharbi M; Alhabeeb L; AlMubarak L; Alaljelaify R; AlSaeed M; Almutairi A; Alqubaishi F; Ahmad M; Al-Banyan A; Alotabi FE; Barakeh D; AlZahrani M; Al-Khalidi H; Ajlan A; Ramkissoon LA; Ramkissoon SH; Abedalthagafi M
PLoS One; 2020; 15(1):e0228356. PubMed ID: 31995621
[TBL] [Abstract][Full Text] [Related]
5. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
[TBL] [Abstract][Full Text] [Related]
6. Multi-institution analysis of tumor mutational burden and outcomes in pediatric central nervous system tumor patients.
Parisi R; Patel RR; Rood G; Bowden A; Turco G; Korones DN; Andolina JR; Comito M; Barth M; Weintraub L
Pediatr Blood Cancer; 2023 Mar; 70(3):e30139. PubMed ID: 36573296
[TBL] [Abstract][Full Text] [Related]
7. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
[TBL] [Abstract][Full Text] [Related]
8. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
Kang H; Pettinga D; Schubert AD; Ladenson PW; Ball DW; Chung JH; Schrock AB; Madison R; Frampton GM; Stephens PJ; Ross JS; Miller VA; Ali SM
Oncologist; 2019 Jun; 24(6):791-797. PubMed ID: 30373905
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive genomic profiling of malignant phyllodes tumors of the breast.
Nozad S; Sheehan CE; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon S; Schrock AB; Hirshfield KM; Ali N; Ganesan S; Ali SM; Miller VA; Stephens PJ; Ross JS; Chung JH
Breast Cancer Res Treat; 2017 Apr; 162(3):597-602. PubMed ID: 28210881
[TBL] [Abstract][Full Text] [Related]
10. General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.
Lee H; El Jabbour T; Ainechi S; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon SH; Ali SM; Schrock A; Fabrizio D; Frampton G; Nazeer T; Miller VA; Stephens PJ; Ross JS
Hum Pathol; 2017 Dec; 70():84-91. PubMed ID: 29079173
[TBL] [Abstract][Full Text] [Related]
11. ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients.
Meredith DM; Cooley LD; Dubuc A; Morrissette J; Sussman RT; Nasrallah MP; Rathbun P; Yap KL; Wadhwani N; Bao L; Wolff DJ; Ida C; Sukhanova M; Horbinski C; Jennings LJ; Farooqi M; Gener M; Ginn K; Kam KL; Sasaki K; Kanagal-Shamanna R; Alexandrescu S; Brat D; Lu X
Mod Pathol; 2023 Nov; 36(11):100294. PubMed ID: 37532182
[TBL] [Abstract][Full Text] [Related]
12. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.
Kline CN; Joseph NM; Grenert JP; van Ziffle J; Talevich E; Onodera C; Aboian M; Cha S; Raleigh DR; Braunstein S; Torkildson J; Samuel D; Bloomer M; Campomanes AGA; Banerjee A; Butowski N; Raffel C; Tihan T; Bollen AW; Phillips JJ; Korn WM; Yeh I; Bastian BC; Gupta N; Mueller S; Perry A; Nicolaides T; Solomon DA
Neuro Oncol; 2017 May; 19(5):699-709. PubMed ID: 28453743
[TBL] [Abstract][Full Text] [Related]
13. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors.
Nikiforova MN; Wald AI; Melan MA; Roy S; Zhong S; Hamilton RL; Lieberman FS; Drappatz J; Amankulor NM; Pollack IF; Nikiforov YE; Horbinski C
Neuro Oncol; 2016 Mar; 18(3):379-87. PubMed ID: 26681766
[TBL] [Abstract][Full Text] [Related]
14. H3F3A K27M mutations in thalamic gliomas from young adult patients.
Aihara K; Mukasa A; Gotoh K; Saito K; Nagae G; Tsuji S; Tatsuno K; Yamamoto S; Takayanagi S; Narita Y; Shibui S; Aburatani H; Saito N
Neuro Oncol; 2014 Jan; 16(1):140-6. PubMed ID: 24285547
[TBL] [Abstract][Full Text] [Related]
15. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Chalmers ZR; Connelly CF; Fabrizio D; Gay L; Ali SM; Ennis R; Schrock A; Campbell B; Shlien A; Chmielecki J; Huang F; He Y; Sun J; Tabori U; Kennedy M; Lieber DS; Roels S; White J; Otto GA; Ross JS; Garraway L; Miller VA; Stephens PJ; Frampton GM
Genome Med; 2017 Apr; 9(1):34. PubMed ID: 28420421
[TBL] [Abstract][Full Text] [Related]
16. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
[TBL] [Abstract][Full Text] [Related]
17. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.
Hodges TR; Ott M; Xiu J; Gatalica Z; Swensen J; Zhou S; Huse JT; de Groot J; Li S; Overwijk WW; Spetzler D; Heimberger AB
Neuro Oncol; 2017 Aug; 19(8):1047-1057. PubMed ID: 28371827
[TBL] [Abstract][Full Text] [Related]
18. Cerebellar high-grade gliomas do not present the same molecular alterations as supratentorial high-grade gliomas and may show histone H3 gene mutations.
Tauziède-Espariat A; Saffroy R; Pagès M; Pallud J; Legrand L; Besnard A; Lacombe J; Lot G; Borha A; Tazi S; Adle-Biassette H; Polivka M; Lechapt E; Varlet P
Clin Neuropathol; 2018; 37(5):209-216. PubMed ID: 29809131
[TBL] [Abstract][Full Text] [Related]
19. Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer.
Abdel-Wahab R; Yap TA; Madison R; Pant S; Cooke M; Wang K; Zhao H; Bekaii-Saab T; Karatas E; Kwong LN; Meric-Bernstam F; Borad M; Javle M
Sci Rep; 2020 Dec; 10(1):22087. PubMed ID: 33328484
[TBL] [Abstract][Full Text] [Related]
20. Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome.
Yang C; Austin F; Richard H; Idowu M; Williamson V; Sabato F; Ferreira-Gonzalez A; Turner SA
Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31604779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]